Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide-Reference-Cited by-同舟云学术

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

Published:2020-02-01 Issue:2 Volume:6 Page:217
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Armstrong Andrew J.¹,Al-Adhami Mohammed²,Lin Ping³,Parli Teresa⁴,Sugg Jennifer⁵,Steinberg Joyce⁶,Tombal Bertrand⁷,Sternberg Cora N.⁸,de Bono Johann⁹,Scher Howard I.¹⁰,Beer Tomasz M.¹¹

Affiliation:

1. Division of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina

2. Biostatistics, Pfizer Inc, Cambridge, Massachusetts

3. Biostatistics, Pfizer Inc, San Francisco, California

4. Clinical Development, Pfizer Inc, San Francisco, California

5. Biostatistics, Astellas Pharma Inc, Northbrook, Illinois

6. Clinical Development, Astellas Pharma Inc, Northbrook, Illinois

7. Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

8. Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York

9. Division of Clinical Studies, The Institute of Cancer Research, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom

10. Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York

11. Division of Hematology/Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2757385/jamaoncology_armstrong_2019_oi_190089.pdf

Reference18 articles.

1. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.;Pollen;AJR Am J Roentgenol,1984

2. Leuprolide therapy for prostate cancer: an association with scintigraphic “flare” on bone scan.;Johns;Clin Nucl Med,1990

3. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.;Scher;J Clin Oncol,2008

4. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.;Scher;J Clin Oncol,2016

5. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.;Ryan;Clin Cancer Res,2011

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer;Med;2024-08

2. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer;Annals of Nuclear Medicine;2024-03-13

3. Pluvicto-Induced 18F-PSMA PET Bone Flare;Clinical Nuclear Medicine;2024-02-22

4. Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus Without Confirmatory Bone Scan;Cancer Research and Treatment;2023-12-05

5. Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer;Reviews on Recent Clinical Trials;2023-05